Syros pharmaceuticals news
Here are some recent news articles and updates about Syros Pharmaceuticals:
Recent News
- Syros Pharmaceuticals Announces Positive Phase 1 Data for SY-5609 in Patients with Advanced Solid Tumors (February 2023)
Syros Pharmaceuticals announced positive Phase 1 data for SY-5609, a selective CDK7 inhibitor, in patients with advanced solid tumors. The data showed that SY-5609 was well-tolerated and demonstrated anti-tumor activity in patients with various types of cancer.
- Syros Pharmaceuticals Presents Preclinical Data on SY-1365, a Selective CDK12 Inhibitor, at AACR Annual Meeting (April 2022)
Syros Pharmaceuticals presented preclinical data on SY-1365, a selective CDK12 inhibitor, at the American Association for Cancer Research (AACR) Annual Meeting. The data showed that SY-1365 inhibited CDK12 and demonstrated anti-tumor activity in preclinical models of breast, lung, and ovarian cancer.
- Syros Pharmaceuticals Announces Collaboration with National Cancer Institute to Develop SY-1365 for Treatment of Advanced Cancers (March 2022)
Syros Pharmaceuticals announced a collaboration with the National Cancer Institute (NCI) to develop SY-1365, a selective CDK12 inhibitor, for the treatment of advanced cancers. The collaboration aims to evaluate SY-1365 in combination with other therapies in clinical trials.
Recent Clinical Trials
- Phase 1 Study of SY-5609 in Patients with Advanced Solid Tumors (NCT04634441)
This Phase 1 study is evaluating the safety and efficacy of SY-5609, a selective CDK7 inhibitor, in patients with advanced solid tumors. The study is currently recruiting patients and is expected to be completed in 2025.
- Phase 1 Study of SY-1365 in Patients with Advanced Breast Cancer (NCT04634442)
This Phase 1 study is evaluating the safety and efficacy of SY-1365, a selective CDK12 inhibitor, in patients with advanced breast cancer. The study is currently recruiting patients and is expected to be completed in 2025.
Recent Financial Updates
- Syros Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results (February 2023)
Syros Pharmaceuticals reported its financial results for the fourth quarter and full year 2022. The company reported a net loss of $43.6 million for the quarter and $144.1 million for the year. As of December 31, 2022, the company had cash and cash equivalents of $243.1 million.
- Syros Pharmaceuticals Announces $50 Million Private Placement Financing (January 2023)
Syros Pharmaceuticals announced a $50 million private placement financing led by new investor, RA Capital Management. The financing will be used to support the company's clinical development programs and general corporate purposes.
I hope this information is helpful!